Latest Industry Insights

There are many reasons that one might want to detect microparticles in a sample, and equally many sources from which microparticles may be generated. Of growing interest recently is the identification of microplastics, not just in the environment but also in the food chain. We spoke to Harald Fischer, Marketing Director at WITec, about ParticleScout, their latest Raman-based solution for rapid identification of microparticles, and the role it can play in assisting microplastic studies.

This year’s Advances in Genome Biology and Technology meeting showcased some of the most exciting developments in genomic technology. We caught up with Twist Bioscience CEO Emily Leproust to discuss the importance of target enrichment in next generation sequencing and the advancements in the field that caught her eye at AGBT.

Despite the great excitement about exosomes and their huge diagnostic and therapeutic potential, the technology needed to advance this work is lacking. We spoke to Jim West, CEO of Clara Biotech, who tells us how his team is working to fill that gap.

Major advances have occurred in the fields of proteomics and genomics over recent years. Now, scientists are utilizing the technologies from each approach collectively in a novel research area named proteogenomics. We spoke with Alexzander Asea, Professor and Director at Precision Therapeutics Proteogenomics Diagnostics Center, University of Toledo, to learn more about the applications of proteogenomics in precision medicine.

Researchers have developed a mathematical model that may offer an alternative to relying on ultrasound information for calculating gestational age. The model, utilizing a "metabolomic fingerprint" approach, may overcome barriers in preterm death research.

Find out how the biopharmaceutical industry has benefited from advances in chromatography technology, with insights from Matthew Lauber, consulting scientist at Waters.

Our recent social media poll on "book recommendations for scientists" provided an incredible response. We decided to collate this information and give you the perfect excuse to treat yourself to a new read. Enjoy!

The thought that compounds in the breath could be measured and assessed to diagnose different aspects of pathology is an exciting prospect. To learn more about the breathalyzer platform being used in clinical trials to detect early cancer biomarkers, we spoke to Chris Claxton, head of investor relations at Owlstone Medical.

Accurate protein characterization is particularly important in the biopharmaceutical industry, where product modifications can affect efficacy and safety. Here, we speak to Matthew Lauber, a consulting scientist who elaborates on the importance and challenges of biotherapeutic protein characterization, and discusses different techniques used for charge variant analysis.

We spoke to Dr Jack Regan, CEO of LexaGene, a biotechnology company developing a fully automated pathogen detection platform, and inventor of their patented microfluidic system, about the foundations and evolution of the system, and the future outlook for the tool.